Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has two oncology programs in clinical development ...
January 26, 2010
Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
November 23, 2009
Human Genome Sciences and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP Inhibitor HGS 1029 in Advanced Lymphoid Tumors
About Aegera
|
Pipeline
|
Clinical Trials
|
Partnerships
|
Media
|
Careers
|
Contact Us
|
Français
© 2009 Aegera Therapeutics Inc. All rights reserved. Developed by
Grafika Designs
.
